U.S. Colorectal Cancer Screening Market is Segmented By Test Type (Fecal Immunochemical Test (FIT), Guaiac-based Fecal Occult Blood Test, Stool DNA Test, and Others), By Imaging Type (Sigmoidoscopy, Colonoscopy, Virtual Colonoscopy, and Others), By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutes, and Others). The report offers the value (in USD billion) for the above-mentioned segments.
Market Size in USD Bn
CAGR7.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 7.5% |
Largest Market | Northeast |
Market Concentration | High |
Major Players | Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, Novigenix SA and Among Others. |
U.S. colorectal cancer screening market size was valued at US$ 5.95 Bn in 2023 and is expected to reach US$ 10.62 Bn by 2031, grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Colorectal cancer is one of the most commonly diagnosed cancers in the U.S. Regular screening is crucial to detect pre-cancerous polyps or early-stage cancer that can then be treated appropriately. Common screening tests include fecal occult blood test (FOBT), Sigmoidoscopy, and colonoscopy. Early detection through screening significantly improves survival rates, yet screening rates remain lower than optimal, especially among racial/ethnic minority and underserved populations.
U.S. colorectal cancer screening market is segmented into test type, imaging type, and end user. U.S. colorectal cancer screening market growth is primarily driven by rising incidence of colorectal cancer and increasing awareness about the importance of early detection. According to the American Cancer Society, in May 2020, colorectal cancer is the third most commonly diagnosed cancer in the U.S. Population aging is another important factor contributing to the market growth as colorectal cancer risk increases with age. However, factors such as lack of symptoms in early stages, lower screening adherence rates, especially in rural areas, and unwillingness to undergo invasive screening tests negatively impact the market. Ongoing innovations in less invasive screening technologies and initiatives to improve screening rates through Medicaid expansions are expected to create significant opportunities for market players in the near future.
U.S. Colorectal Cancer Screening Market- Drivers
U.S. Colorectal Cancer Screening Market- Opportunities
U.S. Colorectal Cancer Screening Market- Restraint
U.S. Colorectal Cancer Screening Market- Regional Insights
Figure 1. U.S. Colorectal Cancer Screening Market Value (US$ Bn), 2023
Major Players operating in the U.S. colorectal cancer screening market include Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, Clinical Genomics Technologies Pty Ltd., Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Illumina, Inc., Myriad Genetics Inc., QIAGEN, Merck KGaA
U.S. Colorectal Cancer Screening Market
New product launches:
Acquisition and partnerships:
Would you like to explore the option of buying individual sections of this report?
What are the key factors hampering growth of the U.S. colorectal cancer screening market?
Risks and complications associated with colorectal cancer screening can hamper the growth of market.
What are the major factors driving the U.S. colorectal cancer screening market growth?
Increasing prevalence of colorectal cancer and growing adoption of non-invasive screening methods are major factors driving the market growth.
Which is the leading test type segment in the U.S. colorectal cancer screening market?
The leading test type segment is the fecal immunochemical test (FIT).
Which are the major players operating in the U.S. colorectal cancer screening market?
Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, Clinical Genomics Technologies Pty Ltd., Abbott, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Illumina, Inc., Myriad Genetics Inc., QIAGEN, Merck KGaA
Which region will lead the U.S. colorectal cancer screening market?
Northeast is expected to lead the U.S. colorectal cancer screening market.
What will be the CAGR of U.S. colorectal cancer screening market?
The CAGR of U.S. colorectal cancer screening market is projected to be 7.5% from 2024-2031.